Biospecifics Technologies Corp (NASDAQ:BSTC) Can’t Be More Risky. Short Interest Increased

Investors sentiment decreased to 1.15 in 2018 Q4. Its down 0.73, from 1.88 in 2018Q3. It worsened, as 5 investors sold BioSpecifics Technologies Corp. shares while 34 reduced holdings. 24 funds opened positions while 21 raised stakes. 3.94 million shares or 4.26% more from 3.78 million shares in 2018Q3 were reported.
Tudor Inv Corporation Et Al holds 3,690 shares. 175 are held by Barclays Public Limited Company. Amer Interest Gru Inc accumulated 3,787 shares. Northpointe Capital Ltd Liability stated it has 0.22% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Goldman Sachs Grp Inc Inc invested in 192,323 shares or 0% of the stock. Denali Advisors Lc reported 49 shares or 0% of all its holdings. Meeder Asset Mgmt invested 0.01% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). D E Shaw & has invested 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Wells Fargo Mn invested 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Sei Investments Com accumulated 1,660 shares or 0% of the stock. Shell Asset Management Company holds 0.01% or 8,061 shares. Rice Hall James Ltd Limited Liability Company accumulated 251,281 shares or 0.56% of the stock. 289,243 were accumulated by Dimensional Fund Advisors Limited Partnership. Morgan Stanley holds 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 9,973 shares. Moreover, Metropolitan Life Insur New York has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC).

The stock of Biospecifics Technologies Corp (NASDAQ:BSTC) registered an increase of 3.06% in short interest. BSTC’s total short interest was 205,400 shares in March as published by FINRA. Its up 3.06% from 199,300 shares, reported previously. With 48,400 shares average volume, it will take short sellers 4 days to cover their BSTC’s short positions. The short interest to Biospecifics Technologies Corp’s float is 5.31%.

The stock decreased 1.67% or $1.13 during the last trading session, reaching $66.59. About 13,257 shares traded. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 78.69% since March 14, 2018 and is uptrending. It has outperformed by 74.32% the S&P500.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $484.63 million. The firm offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 29.59 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: Nasdaq.com which released: “Validea’s Top Five Healthcare Stocks Based On Motley Fool – 2/17/2019 – Nasdaq” on February 17, 2019, also Prnewswire.com with their article: “BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids – PR Newswire” published on October 31, 2018, Nasdaq.com published: “Lannett Set to Lose Distribution Agreement With Key Supplier – Nasdaq” on August 21, 2018. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: Nasdaq.com and their article: “Western Digital (WDC) Q2 Earnings, Revenues Lag Estimates – Nasdaq” published on January 25, 2019 as well as Nasdaq.com‘s news article titled: “Should You Buy CVS Stock Ahead of Q3 Earnings? – Nasdaq” with publication date: November 02, 2018.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.